Not admitted · Vague or promotional

Review of Cobenfy (xanomeline-trospium), newly FDA-approved for schizophrenia. After noting its side effects are annoying but not life-threatening, the author expects more adverse effects to be discovered once the drug is used at large scale.

No entity, observable event, benchmark or threshold can be written from the text and its immediate context. Slogans ('game changer', 'once-in-a-lifetime opportunity', 'favourite stock') and quantifiers with no countable set ('more', 'first', 'all') without a defined set.